Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi-Aventis 3Q09 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Sanofi-Aventis 3Q09

Pharmaceutical sales were up 6% to $9.3 billion in the quarter and YTD sales rose 4% to $28.5 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi-Aventis 3Q09

3Q Revenues: $10.8 billion (+8%)

3Q Earnings:$3.3 billion (+16%)

YTD Revenues: $32.0 billion (+7%)

YTD Earnings: $6.7 billion (+20%)

Comments: Pharmaceutical sales were up 6% to $9.3 billion in the quarter and YTD sales rose 4% to $28.5 billion. Exchange rates favorably effected results by 2% and 3%, respectively. Lovenox and Lantus sales reached $1.1 billion, up 14% and 22%, respectively. Plavix sales were $968.9 million (+4%). Apidra sales were up 32% in the quarter to $49.6 million. Sales of Eloxatin were $281.6 million (-44%) due to generic competition. The company launched Multaq, an anti-arrhythmic, in the U.S. with sales of $19.0 million. Human Vaccines revenue rose 5% to $1.5 billion, driven by the performance of Pentacel, Pentaxim and Menactra, as well as the first H1N1 shipments.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters